Related references
Note: Only part of the references are listed.Recommended changes to oncology clinical trial design: Revolution or evolution?
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2008)
Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)
Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III
Robert H. El-Maraghi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo
Alicia A. Goyeneche et al.
CLINICAL CANCER RESEARCH (2007)
Discovery of novel epigenetic markers in non-Hodgkin's lymphoma
Huidong Shi et al.
CARCINOGENESIS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multiscale model for avascular tumor growth
Y Jiang et al.
BIOPHYSICAL JOURNAL (2005)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evaluation of randomized discontinuation design
B Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints
WB Capra
CONTROLLED CLINICAL TRIALS (2004)
Breast and ovarian cancer
R Wooster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized discontinuation design: Application to cytostatic antineoplastic agents
GL Rosner et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Application of a new multinomial phase II stopping rule using response and early progression
S Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
